Overexpression of SERPINA3 promotes tumor invasion and migration, epithelial-mesenchymal-transition in triple-negative breast cancer cells
Open Access
- 10 February 2021
- journal article
- research article
- Published by Springer Nature in Breast Cancer
- Vol. 28 (4) , 859-873
Abstract
Background: Recent studies have indicated that serpin peptidase inhibitor, clade A, member 3 (SERPINA3) is a potential marker associated with tumor progression, which connoted that SERPINA3 is related to malignant phenotypes in cancer. However, the biological function of SERPINA3 in breast cancer (BC) remains unclear. Methods: Bioinformatics data were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Immunohistochemical staining (IHC) was conducted to determine SERPINA3 expression. With strong aggressive abilities, triple-negative breast cancer (TNBC) cell lines (MDA-MB-231, BT549 and MDA-MB-436) were obtained to examine SERPINA3 expression and functions. Wound healing and Transwell assays were performed to measure cell migration and invasion. Cell Counting Kit-8 (CCK-8) assay was conducted to detect cell proliferation abilities and cell viabilities. Results: SERPINA3 was upregulated in BC tissues. Functional assays suggested that overexpression of SERPINA3 significantly promoted cell proliferation, where migration and invasion of TNBC cells were accelerated. Knockdown of SERPINA3 had the opposite effects. These results causing by overexpression of SERPINA3 were also confirmed in non-TNBC cell lines. Overexpression of SERPINA3 remarkably enhanced the epithelial–mesenchymal transition (EMT) by upregulating the EMT markers and EZH2. In addition, the overexpression of SERPINA3 reduced the sensitivity of TNBC cells to cisplatin. Conclusion: SERPINA3 can regulate the migration, invasion and EMT of TNBC cells and increased expression of SERPINA3 confers resistance to cisplatin in TNBC cells. We discern it is required for the regulation of BC progression and is a critical target for the clinical treatment of BC.Keywords
Funding Information
- The National Natural Science Foundation of China (81772979)
This publication has 32 references indexed in Scilit:
- Breast cancer stem cells, EMT and therapeutic targetsBiochemical and Biophysical Research Communications, 2014
- Enhancer of zeste homolog 2: A potential target for tumor therapyThe International Journal of Biochemistry & Cell Biology, 2011
- Regulation of Pancreatic Tumor Cell Proliferation and Chemoresistance by the Histone Methyltransferase Enhancer of Zeste Homologue 2Clinical Cancer Research, 2008
- Epithelial—mesenchymal and mesenchymal—epithelial transitions in carcinoma progressionJournal of Cellular Physiology, 2007
- SERPINA3 (aka alpha-1-antichymotrypsin)Frontiers in Bioscience-Landmark, 2007
- Inflammation and cancerNature, 2002
- Glioma cell activation by Alzheimer's peptide Aβ 1–42, α 1-antichymotrypsin, and their mixtureCellular and Molecular Life Sciences, 2002
- α1‐Antichymotrypsin/Alzheimer's peptide Aβ1–42 complex perturbs lipid metabolism and activates transcription factors PPARγ and NFκB in human neuroblastoma (Kelly) cellsJournal of Neuroscience Research, 2002
- Molekulare Formen des prostataspezifischen Antigens und des humanen Kallikreins 2 als mögliche Indikatoren in der ProstatakarzinomdiagnostikDer Urologe, 2000
- α1-antichymotrypsinThe International Journal of Biochemistry & Cell Biology, 1996